Penetrium Bioscience Surges 17% on Positive Prostate Cancer Trial Results
What happened
Penetrium Bioscience reported encouraging responses in an early-stage clinical trial for its prostate cancer drug candidate. Hyundai Bioscience announced that two patients who had developed resistance to existing anticancer therapies showed reduction. Following this news, Penetrium Bioscience shares closed at 6,750 won on November 19, up 17.19%.
From edaily.co.kr
Why it matters
The positive clinical trial results drove investor sentiment across South Korean pharmaceutical and biotechnology stocks. The success of the drug candidate could positively affect the business and investment prospects of Hyundai Bioscience.
From edaily.co.kr
Who's involved
- Hyundai BioscienceParent company of Penetrium Bioscience
- Seoul National University HospitalHospital where the clinical trial is being conducted
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Hyundai BioscienceSpeculative
Hyundai Bioscience might see increased investment and revenue potential due to the positive clinical trial results for its subsidiary.
- Seoul National University HospitalSpeculative
Seoul National University Hospital could see enhanced research funding and contracts due to its involvement in the successful clinical trial.
Keep exploring
The entities involved
-
Seoul National University Hospital
hospital in Seoul, South Korea
Nothing else this week.